Novo Nordisk ASMEX:NVON -0.60%76 Pretax Margin % is 64.21% as of Mar. 2026, which is 51% above its 10-year median of 42.41. GuruFocus rates MEX:NVON with a GF Score™ of 76/100 and a GF Value™ of MXN2,387.52 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Novo Nordisk AS ranks better than 96.96% on this metric.
The historical rank and industry rank for Novo Nordisk AS's Pretax Margin % or its related term are showing as below:
MEX:NVON'
s Pretax Margin % Range Over the Past 10 Years
Min: 39.03 Med: 42.41 Max: 47.49
Current: 47.49
MEX:NVON's Pretax Margin % is ranked better than 96.96% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs MEX:NVON: 47.49
Novo Nordisk AS (MEX:NVON) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Novo Nordisk AS Pretax Margin % Related Terms
Novo Nordisk AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVON vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NVON) has a Pretax Margin % of 64.21% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novo Nordisk AS and its competitors. This is 51% above median its historical median of 42.41. Over the past decade, Novo Nordisk AS's Pretax Margin % has ranged from 39.03 to 47.49. According to the industry distribution chart, Novo Nordisk AS ranks #29 out of 955 companies in the Drug Manufacturers industry, placing it in the top 3%.
Is Novo Nordisk AS's Pretax Margin % too high?
Novo Nordisk AS's current Pretax Margin % of 64.21% is 51% above median its 10-year median of 42.41. Over the past 10 years, this metric has ranged from a low of 39.03 to a high of 47.49. The Drug Manufacturers industry median Pretax Margin % is 7.28. Novo Nordisk AS's value of 64.21% is 782% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #29 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #29 out of 955 companies for Pretax Margin %. This places Novo Nordisk AS in the top 3% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Novo Nordisk AS's value of 64.21% is 782% above this benchmark. Historically, Novo Nordisk AS's own Pretax Margin % has ranged from 39.03 to 47.49 over the past decade. While the company's 10-year median is 42.41 vs. the industry median of 7.28, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Pretax Margin % of 64.21% is 782% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Pretax Margin % is 64.21%, which is 51% above median its own 10-year median of 42.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NVON) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.52, compared to a current price of MXN831.50 — trading 65.2% below its estimated fair value. The current Pretax Margin % is 64.21%, which is 51% above median its 10-year median of 42.41 and 782% above the Drug Manufacturers industry median of 7.28. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NVON), the current Pretax Margin % is 64.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NVON) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN831.50 is trading 65.2% below its estimated GF Value™ of MXN2,387.52.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NVON:
Pretax Margin %: 64.21% (51% above median its 10-year median of 42.41)
GF Value™: MXN2,387.52 vs. price of MXN831.50 (65.2% below fair value)
Industry Position: 782% above the Drug Manufacturers median (#29 of 955)
No single metric tells the full story. See the MEX:NVON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score
Get the complete analysis for MEX:NVON
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVON has been successfully added to your 
